BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26

• Press Releases

  A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer

  May 22, 2026

   · 

  6 min read
• Press Releases

  OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

  May 22, 2026

   · 

  7 min read
• Press Releases

  Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer

  May 22, 2026

   · 

  5 min read
• Press Releases

  Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting

  May 22, 2026

   · 

  7 min read
• Press Releases

  Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

  May 22, 2026

   · 

  11 min read
• Press Releases

  HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

  May 22, 2026

   · 

  11 min read
• Press Releases

  Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

  May 22, 2026

   · 

  5 min read
• Press Releases

  2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety

  May 22, 2026

   · 

  10 min read
• Press Releases

  2026 ASCO Abstract Highlights: Innovent Biologics’ IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

  May 22, 2026

   · 

  7 min read
• Press Releases

  Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026

  May 22, 2026

   · 

  10 min read